<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05110482</url>
  </required_header>
  <id_info>
    <org_study_id>MD-247-2020</org_study_id>
    <nct_id>NCT05110482</nct_id>
  </id_info>
  <brief_title>Carbetocin Versus Syntocinon for Prevention of Postpartum Hemorrhage in Cardiac Patients Undergoing Caesarean Section</brief_title>
  <official_title>Carbetocin Versus Syntocinon for Prevention of Postpartum Hemorrhage in Cardiac Patients With Stenotic Valvular Heart Disease Undergoing Caesarean Section</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cairo University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cairo University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Postpartum hemorrhage (PPH) is the primary cause of nearly one quarter of all maternal deaths&#xD;
      globally. Management of uterine tone after delivery involves giving a prophylactic uterotonic&#xD;
      and the use of controlled cord traction to facilitate delivery of the placenta and minimize&#xD;
      blood loss. Syntocinon and carbetocin are the most commonly used drugs ,During caesarean&#xD;
      delivery of stenotic valvular disease patient, the anesthesiologist have an important&#xD;
      question: what is the best drug used for prevention of PPH with minimal hemodynamic effect&#xD;
      regarding Systemic vascular resistance (SVR), Cardiac out put (COP),Heart rate ( HR), blood&#xD;
      pressure? As uterotonic drugs may cause severe hypotension, decrease in SVR and COP that may&#xD;
      not be tolerated by these patients .this thesis aims to compare between syntocinon and&#xD;
      carbetocin regarding their effect on cardiac output and systemic vascular resistance using&#xD;
      cardiometry in cardiac patients with stenotic lesions during caesarean delivery.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 30, 2021</start_date>
  <completion_date type="Anticipated">April 2022</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cardiac output</measure>
    <time_frame>intraoperative</time_frame>
    <description>Average Cardiac output after study drug administration</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>systemic vascular resistance</measure>
    <time_frame>intraoperative</time_frame>
    <description>Systemic vascular resistance every 2 minute till end of surgery</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">38</enrollment>
  <condition>Adverse Effect of Oxytocic Drugs</condition>
  <arm_group>
    <arm_group_label>syntocinon group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>in this group :5 mL syringe containing a bolus of 1 IU of oxytocin and infusion syringe which will be prepared with a 50 mL syringe containing 0.4 IU/mL of oxytocin and infusion rate of 7.5 IU/h will be administrated to the patient after delivery of the fetus shoulder, Additional bolus syringes will be prepared for use as rescue boluses if needed &quot; which will be 5 ml syringe containing 3 IU of oxytocin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>carbetocin group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>in this group :5 mL syringe containing a bolus of 100 mcg of carbetocin and infusion syringe &quot; which will be prepared with a 50 mL syringe containing normal saline will be administrated for the patient after delivery of the fetus shoulder. Additional bolus syringes will be prepared for use as rescue boluses if needed which will be 5 ml syringe containing 100 mcg of carbetocin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Syntocinon</intervention_name>
    <description>uterotonic drugs</description>
    <arm_group_label>syntocinon group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carbetocin</intervention_name>
    <description>uterotonic drug</description>
    <arm_group_label>carbetocin group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Pregnant female single tone &gt;38 weeks&#xD;
&#xD;
          -  Age :18-45 years old.&#xD;
&#xD;
          -  patient with ASA III&#xD;
&#xD;
          -  Cardiac patients ( mild and moderate mitral stenosis-aortic stenosis valve disease )&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Other cardiac conditions (valve regurge, cardiomyopathy, heart failure,severe mitral&#xD;
             stenosis, severe aortic stenosis, severe pulmonary hypertension)&#xD;
&#xD;
          -  Pregnancy hypertensive disorders (eclampsia,preeclampsia)&#xD;
&#xD;
          -  Abnormal placental attachment (accrete,percreta,increta)&#xD;
&#xD;
          -  Patients with bleeding disorders&#xD;
&#xD;
          -  patient with high risk of postpartum haemorrhage&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>pregnant females presented for caesarean delivery</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 28, 2021</study_first_submitted>
  <study_first_submitted_qc>October 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 8, 2021</study_first_posted>
  <last_update_submitted>October 26, 2021</last_update_submitted>
  <last_update_submitted_qc>October 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cairo University</investigator_affiliation>
    <investigator_full_name>Sherin Refaat</investigator_full_name>
    <investigator_title>Assistant professor of anesthiology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Postpartum Hemorrhage</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxytocin</mesh_term>
    <mesh_term>Carbetocin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

